Cipepofol
As of the edition of 20 October 2026, Cipepofol is a small molecule: marketed, first approved in 2026 (US); US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Cypsedo
- First approved
- 27 August 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Haisco-USA Pharmaceuticals
- Registered trials
- 81, 1 stopped early
- Disease areas
- Digestive system; Heart and blood vessels; Nervous system; Cancer; Lungs and airways; Mental health
US protection
US protection ends in 2031.
The last listed US exclusivity ends in 2031. The application that gives this date is held by Haisco-USA Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 23 | 3 | 8 | 0 |
| Phase 1 | 17 | 14 | 0 | 1 |
| Phase 2 | 6 | 6 | 0 | 0 |
| Phase 3 | 11 | 10 | 1 | 0 |
| Phase 4 | 24 | 8 | 11 | 0 |
| All trials | 81 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Haisco-USA Pharmaceuticals | Originator and Lead sponsor of trials | 2021 to now |